Aripiprazole-related tardive dyskinesia.
The low prevalence of extrapyramidal symptoms associated with atypical antipsychotics has led to their widespread use during the past decade. Aripiprazole, the newest medication in this class, has been associated with extrapyramidal symptoms (eg, akathisia) and with improvement of tardive dyskinesia (TD), but to date it has not been associated with the development of TD. We report a case of TD associated with the use of aripiprazole 15 mg/day for 18 months for refractory depression. Symptoms of TD resolved within several weeks of discontinuation of aripiprazole.
Maytal
Guy
G
Psychiatric Consultation Service, Massachusetts General Hospital, Boston, MA 02114, USA. gmaytal@partners.org
Ostacher
Michael
M
Stern
Theodore A
TA
D014150:Antipsychotic Agents / Q000009:adverse effects*; D000068180:Aripiprazole; D003865:Major Depressive Disorder / Q000188:drug therapy*; D004409:Dyskinesia, Drug-Induced / Q000209:etiology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects*; D015363:Quinolones / Q000009:adverse effects*
D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole